{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:41:22Z","timestamp":1786286482486,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,9]]},"DOI":"10.7759\/cureus.114201","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:52:22Z","timestamp":1786283542000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-CGRP Monoclonal Antibodies in Chronic Migraine: A Position Statement of the Brazilian Academy of Headache and Orofacial Pain"],"prefix":"10.7759","author":[{"given":"Abouch","family":"Krymchantowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilton Mariano da Silva","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo Pereira","family":"Silva-N\u00e9to","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Jevoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Luiz C","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos  A","family":"Bordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Augusto C","family":"De Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela G","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lcio","family":"Piovesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Dach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio","family":"Rezende Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pereira J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Fortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackeline","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Olavo","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Stechman Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Stuginski Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bruscky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Pinto Vidor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Silva Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz P","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Bigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus T","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia Veluttini","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Beiral Hammerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro Luiz de Andrade","family":"Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Novaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanise","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.37506\/pfganq29","article-title":"Letter to editor for raising awareness for cutting-edge treatments for chronic migraine \u2018\u2019use of CGRP inhibitors, TMS and relaxation techniques\"","volume":"10","author":"Umer S","year":"2024","unstructured":"Umer S. Letter to editor for raising awareness for cutting-edge treatments for chronic migraine \u2018\u2019use of CGRP inhibitors, TMS and relaxation techniques\". IJCPath. 2024, 10:5-6. 10.37506\/pfganq29","journal-title":"IJCPath"},{"key":"ref2","article-title":"Headache and Facial Pain","author":"Newman LC","year":"2022","unstructured":"Newman LC, Levin M, Halker SRB, et al.. Headache and Facial Pain. Oxford University Press USA, New York, NY; 2022."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5281\/ZENODO.13955285","article-title":"A review article on migraine and food supplements in the management of migraine headaches","author":"Siddhartha LPR","year":"2024","unstructured":"Siddhartha LPR. A review article on migraine and food supplements in the management of migraine headaches. Int J Pharm Sci. 2024, 10.5281\/ZENODO.13955285","journal-title":"Int J Pharm Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/head.14123","article-title":"Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: a real-life perspective from the Italian chROnic migraiNe (IRON) project","volume":"61","author":"Barbanti P","year":"2021","unstructured":"Barbanti P, Fofi L, Grazzi L, et al.. Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: a real-life perspective from the Italian chROnic migraiNe (IRON) project. Headache. 2021, 61:936-50. 10.1111\/head.14123","journal-title":"Headache"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.705276","article-title":"Chronic migraine pathophysiology and treatment: a review of current perspectives","volume":"2","author":"Mungoven TJ","year":"2021","unstructured":"Mungoven TJ, Henderson LA, Meylakh N. Chronic migraine pathophysiology and treatment: a review of current perspectives. Front Pain Res (Lausanne). 2021, 2:705276. 10.3389\/fpain.2021.705276","journal-title":"Front Pain Res (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01954.x","article-title":"Chronic migraine, classification, differential diagnosis, and epidemiology","volume":"51 Suppl 2","author":"Lipton RB","year":"2011","unstructured":"Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011, 51 Suppl 2:77-83. 10.1111\/j.1526-4610.2011.01954.x","journal-title":"Headache"},{"key":"ref7","article-title":"Medication overuse headache","volume":"98","author":"Lenaerts ME","year":"2007","unstructured":"Lenaerts ME, Couch JR. Medication overuse headache. Minerva Med. 2007, 98:221-31.","journal-title":"Minerva Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-013-1359-z","article-title":"Psychiatric screening for migraine patients","volume":"34","author":"Gambini O","year":"2013","unstructured":"Gambini O, Biagianti B, Grazzi L, Usai S, Scarone S, Bussone G. Psychiatric screening for migraine patients. Neurol Sci. 2013, 34:S61-6. 10.1007\/s10072-013-1359-z","journal-title":"Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053","article-title":"Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study","volume":"61","author":"Kawata AK","year":"2021","unstructured":"Kawata AK, Shah N, Poon JL, et al.. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache. 2021, 61:438-54. 10.1111\/head.14053","journal-title":"Headache"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0533-9","article-title":"Update on the pharmacological treatment of chronic migraine","volume":"20","author":"Sun-Edelstein C","year":"2016","unstructured":"Sun-Edelstein C, Rapoport AM. Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep. 2016, 20:6. 10.1007\/s11916-015-0533-9","journal-title":"Curr Pain Headache Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.30756\/ahmj.2020.01.03","article-title":"CGRP therapeutics for the treatment of migraine - a narrative review","volume":"1","author":"Yuan H","year":"2020","unstructured":"Yuan H. CGRP therapeutics for the treatment of migraine - a narrative review. Ann Head Med. 2020, 1:3. 10.30756\/ahmj.2020.01.03","journal-title":"Ann Head Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1671350","article-title":"Monoclonal antibodies for the prevention of migraine","volume":"19","author":"Raffaelli B","year":"2019","unstructured":"Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. 2019, 19:1307-17. 10.1080\/14712598.2019.1671350","journal-title":"Expert Opin Biol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-025-01365-4","article-title":"Review: an update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine","volume":"29","author":"Nicol KS","year":"2025","unstructured":"Nicol KS, Burkett JG. Review: an update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine. Curr Pain Headache Rep. 2025, 29:55. 10.1007\/s11916-025-01365-4","journal-title":"Curr Pain Headache Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14090948","article-title":"Calcitonin gene-related peptide monoclonal antibodies: key lessons from real-world evidence","volume":"14","author":"Orlando B","year":"2024","unstructured":"Orlando B, Egeo G, Aurilia C, Fiorentini G, Barbanti P. Calcitonin gene-related peptide monoclonal antibodies: key lessons from real-world evidence. Brain Sci. 2024, 14:948. 10.3390\/brainsci14090948","journal-title":"Brain Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15101119","article-title":"FDA-regulated clinical trials vs. real-world data: how to bridge the gap in pain research","volume":"15","author":"Reyes A","year":"2025","unstructured":"Reyes A, Malik M, Sahouri M, Knezevic NN. FDA-regulated clinical trials vs. real-world data: how to bridge the gap in pain research. Brain Sci. 2025, 15:1119. 10.3390\/brainsci15101119","journal-title":"Brain Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-anzan.26","article-title":"027 Will refractory patients respond to erenumab in the real world?","volume":"90","author":"Jenkins B","year":"2019","unstructured":"Jenkins B, Cheng S, Hutton E. 027 Will refractory patients respond to erenumab in the real world?. J Neurol Neurosurg Psychiatry. 2019, 90:10-1. 10.1136\/jnnp-2019-anzan.26","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac059","article-title":"Machine prescription for chronic migraine","volume":"4","author":"Stubberud A","year":"2022","unstructured":"Stubberud A, Gray R, Tronvik E, Matharu M, Nachev P. Machine prescription for chronic migraine. Brain Commun. 2022, 4:fcac059. 10.1093\/braincomms\/fcac059","journal-title":"Brain Commun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02158-1","article-title":"Bridging the gap between evidence and clinical practice for migraine headaches: a systematic review (2019-2024)","volume":"26","author":"Chen E","year":"2025","unstructured":"Chen E, Rowe M, Khan A, et al.. Bridging the gap between evidence and clinical practice for migraine headaches: a systematic review (2019-2024). J Headache Pain. 2025, 26:226. 10.1186\/s10194-025-02158-1","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s43999-022-00017-z","article-title":"The atlas of variation in healthcare Brazil: remarkable findings from a middle-income country","volume":"2","author":"Diegoli H","year":"2023","unstructured":"Diegoli H, Makdisse M, Magalh\u00e3es P, Gray M. The atlas of variation in healthcare Brazil: remarkable findings from a middle-income country. Res Health Serv Reg. 2023, 2:2. 10.1007\/s43999-022-00017-z","journal-title":"Res Health Serv Reg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231167953","article-title":"IBD barriers across the continents: a continent-specific analysis: Latin America","volume":"16","author":"Queiroz NS","year":"2023","unstructured":"Queiroz NS, Martins CA, Quaresma AB, Olivera Sendra PA, Ernest-Suarez K, Kotze PG. IBD barriers across the continents: a continent-specific analysis: Latin America. Ther Adv Gastroenterol. 2023, 16:3. 10.1177\/17562848231167953","journal-title":"Ther Adv Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38390","article-title":"A closer look into Brazil's healthcare system: what can we learn?","volume":"15","author":"Roman A","year":"2023","unstructured":"Roman A. A closer look into Brazil's healthcare system: what can we learn?. Cureus. 2023, 15:e38390. 10.7759\/cureus.38390","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02265-z","article-title":"Factors contributing to inaccurate migraine diagnosis: a prospective study at a tertiary hospital in Southern Thailand","volume":"27","author":"Suwanlaong K","year":"2025","unstructured":"Suwanlaong K, Sittisomwong S, Dutsadeethammo D, Anukoolwittaya P, Rattanawong W. Factors contributing to inaccurate migraine diagnosis: a prospective study at a tertiary hospital in Southern Thailand. J Headache Pain. 2025, 27:35. 10.1186\/s10194-025-02265-z","journal-title":"J Headache Pain"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_376_19","article-title":"Factors associated with delayed diagnosis of migraine: a hospital-based cross-sectional study","volume":"8","author":"Rai NK","year":"2019","unstructured":"Rai NK, Bitswa R, Singh R, Pakhre AP, Parauha DS. Factors associated with delayed diagnosis of migraine: a hospital-based cross-sectional study. J Family Med Prim Care. 2019, 8:1925-30. 10.4103\/jfmpc.jfmpc_376_19","journal-title":"J Family Med Prim Care"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11880-2","article-title":"Risk factors for migraine disease progression: a narrative review for a patient-centered approach","volume":"270","author":"Lipton RB","year":"2023","unstructured":"Lipton RB, Buse DC, Nahas SJ, et al.. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023, 270:5692-710. 10.1007\/s00415-023-11880-2","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00387-9","article-title":"Practical insights on the identification and management of patients with chronic migraine","volume":"11","author":"Blumenfeld A","year":"2022","unstructured":"Blumenfeld A, Dueland AN, Evers S, Jenkins B, Martelletti P, Sommer K. Practical insights on the identification and management of patients with chronic migraine. Pain Ther. 2022, 11:447-57. 10.1007\/s40122-022-00387-9","journal-title":"Pain Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/life14091146","article-title":"Medication-overuse headache: update on management","volume":"14","author":"Koonalintip P","year":"2024","unstructured":"Koonalintip P, Phillips K, Wakerley BR. Medication-overuse headache: update on management. Life (Basel). 2024, 14:1146. 10.3390\/life14091146","journal-title":"Life (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00331-3","article-title":"Burden of migraine in patients with preventive treatment failure attending European headache specialist centers: real-world evidence from the BECOME study","volume":"10","author":"Pozo-Rosich P","year":"2021","unstructured":"Pozo-Rosich P, Lucas C, Watson DP, et al.. Burden of migraine in patients with preventive treatment failure attending European headache specialist centers: real-world evidence from the BECOME study. Pain Ther. 2021, 10:1691-708. 10.1007\/s40122-021-00331-3","journal-title":"Pain Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1090878","article-title":"Associations between anxiety, depression with migraine, and migraine-related burdens","volume":"14","author":"Duan S","year":"2023","unstructured":"Duan S, Ren Z, Xia H, et al.. Associations between anxiety, depression with migraine, and migraine-related burdens. Front Neurol. 2023, 14:1090878. 10.3389\/fneur.2023.1090878","journal-title":"Front Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104943","article-title":"Resistant and refractory migraine: clinical presentation, pathophysiology, and management","volume":"99","author":"Ornello R","year":"2024","unstructured":"Ornello R, Andreou AP, De Matteis E, J\u00fcrgens TP, Minen MT, Sacco S. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. 2024, 99:104943. 10.1016\/j.ebiom.2023.104943","journal-title":"EBioMedicine"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04384-1","article-title":"Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study","volume":"25","author":"Cardona-Roca L","year":"2025","unstructured":"Cardona-Roca L, Segu\u00ed-Solanes C, Cano-Alonso M, Sosa-Pons A, Almendros-Abad N, Sola NR. Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study. BMC Neurol. 2025, 25:418. 10.1186\/s12883-025-04384-1","journal-title":"BMC Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00769-z","article-title":"Disrupting migraine dynamics: a narrative review of the consequences of modern anti-CGRP monoclonal antibody therapies","volume":"14","author":"Buse DC","year":"2025","unstructured":"Buse DC, Versijpt J, Diener HC. Disrupting migraine dynamics: a narrative review of the consequences of modern anti-CGRP monoclonal antibody therapies. Neurol Ther. 2025, 14:1185-96. 10.1007\/s40120-025-00769-z","journal-title":"Neurol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02256-0","article-title":"Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review","volume":"27","author":"Hoehne CL","year":"2026","unstructured":"Hoehne CL, Overeem LH, Sanchez-Del-Rio M, et al.. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. J Headache Pain. 2026, 27:10. 10.1186\/s10194-025-02256-0","journal-title":"J Headache Pain"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91347","article-title":"Patient adherence and long-term tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in migraine prevention: a systematic review","volume":"17","author":"Ray R","year":"2025","unstructured":"Ray R, Virk GS, Regmi N, et al.. Patient adherence and long-term tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in migraine prevention: a systematic review. Cureus. 2025, 17:e91347. 10.7759\/cureus.91347","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237329","article-title":"Comparative study of the efficacy of anti-CGRP mAbs on migraineurs: analysis of the first year of therapy, 1-month suspension period, and reprisal","volume":"12","author":"Tereshko Y","year":"2023","unstructured":"Tereshko Y, Dal Bello S, Pez S, et al.. Comparative study of the efficacy of anti-CGRP mAbs on migraineurs: analysis of the first year of therapy, 1-month suspension period, and reprisal. J Clin Med. 2023, 12:7329. 10.3390\/jcm12237329","journal-title":"J Clin Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_95_22","article-title":"Advances in CGRP monoclonal antibodies as migraine therapy: a narrative review","volume":"11","author":"Aditya S","year":"2023","unstructured":"Aditya S, Rattan A. Advances in CGRP monoclonal antibodies as migraine therapy: a narrative review. Saudi J Med Med Sci. 2023, 11:11-8. 10.4103\/sjmms.sjmms_95_22","journal-title":"Saudi J Med Med Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050224-111631","article-title":"CGRP and migraine: real-world insights and future therapeutic directions","volume":"77","author":"Russo AF","year":"2026","unstructured":"Russo AF, Kaiser EA. CGRP and migraine: real-world insights and future therapeutic directions. Annu Rev Med. 2026, 77:415-32. 10.1146\/annurev-med-050224-111631","journal-title":"Annu Rev Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1809332","article-title":"Calcitonin gene-related peptide monoclonal antibodies and medication-overuse headache: stopping excessive pain medication is still necessary","volume":"83","author":"Rocha-Filho PA","year":"2025","unstructured":"Rocha-Filho PA. Calcitonin gene-related peptide monoclonal antibodies and medication-overuse headache: stopping excessive pain medication is still necessary. Arq Neuropsiquiatr. 2025, 83:1-4. 10.1055\/s-0045-1809332","journal-title":"Arq Neuropsiquiatr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/head.14528","article-title":"A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine","volume":"63","author":"Sacc\u00e0 F","year":"2023","unstructured":"Sacc\u00e0 F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R, Russo CV. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine. Headache. 2023, 63:788-94. 10.1111\/head.14528","journal-title":"Headache"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.102829","article-title":"Reframing clinical research in Latin America: implications of underrepresentation for health systems and global evidence","volume":"18","author":"Zavaleta-Monestel E","year":"2026","unstructured":"Zavaleta-Monestel E, Mart\u00ednez-Vargas E, Mora-Jim\u00e9nez J, Arguedas-Chac\u00f3n S. Reframing clinical research in Latin America: implications of underrepresentation for health systems and global evidence. Cureus. 2026, 18:e102829. 10.7759\/cureus.102829","journal-title":"Cureus"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01918-9","article-title":"Epidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022","volume":"25","author":"Rubio AC","year":"2024","unstructured":"Rubio AC, Arciniegas JA, Bolanos-Lopez JE, et al.. Epidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022. J Headache Pain. 2024, 25:226. 10.1186\/s10194-024-01918-9","journal-title":"J Headache Pain"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019","volume":"163","author":"Safiri S","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, et al.. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022, 163:e293-309. 10.1097\/j.pain.0000000000002275","journal-title":"Pain"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504805-anti-cgrp-monoclonal-antibodies-in-chronic-migraine-a-position-statement-of-the-brazilian-academy-of-headache-and-orofacial-pain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:52:23Z","timestamp":1786283543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504805-anti-cgrp-monoclonal-antibodies-in-chronic-migraine-a-position-statement-of-the-brazilian-academy-of-headache-and-orofacial-pain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.114201","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}